# THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)

> **NCT05033314** · PHASE3 · TERMINATED · sponsor: **University Health Network, Toronto** · enrollment: 4 (actual)

## Conditions studied

- Sickle Cell Disease
- Central Venous Catheter Thrombosis
- Venous Thromboembolism

## Interventions

- **DRUG:** Rivaroxaban 10 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05033314
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-07
- **Primary completion:** 2024-10-01
- **Final completion:** 2024-10-01
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Study terminated due to slow recruitment.
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05033314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05033314, "THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05033314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*